Glaukos Announces Executive Leadership Changes
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several executive leadership changes to support the company’s future growth and strategic plans. The following executive changes will become effective on April 1, 2022:
- Joseph Gilliam will assume the new role of President and Chief Operating Officer. Mr. Gilliam has served as Chief Financial Officer and Senior Vice President, Corporate Development since joining Glaukos in May 2017 from J.P. Morgan.
- Chris Calcaterra will assume the new role of Executive Vice President, Global Commercial Operations. Mr. Calcaterra joined Glaukos in April 2008 as Chief Commercial Officer and has served as Chief Operating Officer since February 2017.
- Alex Thurman will succeed Mr. Gilliam to become Senior Vice President, Chief Financial Officer. Mr. Thurman joined Glaukos as Vice President, Global Tax and Administration in July 2016 from Allergan and has served as Vice President, Finance since December 2016.
- Tomas Navratil, Ph.D., will assume the new role of Chief Development Officer. Dr. Navratil has served as Senior Vice President, Research and Development since joining Glaukos in October 2020.
“On behalf of the entire Glaukos organization, I am delighted to congratulate Joe, Alex and Tomas on these well-deserved promotions and pledge our full support to them in their new roles that bring expanded leadership responsibilities in alignment with our long-term strategic objectives. I am confident these outstanding and proven leaders will continue to successfully drive Glaukos forward in the next phase of our pioneering journey and help further advance our mission to transform the treatment of chronic eye diseases for the benefit of patients worldwide,” said Thomas Burns, Glaukos Chairman and CEO. “At the same time, I want to extend my sincere congratulations to my friend and colleague Chris Calcaterra on his requested transition into his new role. Chris has been instrumental in the growth and development of Glaukos since joining our management team nearly fourteen years ago. I am confident he will continue to play an integral role in our success in his new position that will provide Chris with the opportunity to step back from his day-to-day administrative responsibilities and spend more time with his family, while continuing to focus on our global commercial operations, his deep customer relationships built over the past 35 years and ongoing strategic counsel to our executive and commercial leadership teams.”
Read the full press release here.
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809